Loading…
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $10M | $-156M | $-114M | $-83M | -11.9% | -5.6% | 64.7% |
| 2024 | $11M | $-97M | $-69M | $-44M | -6.7% | 31.0% | 18.4% |
| 2023 | $8M | $-71M | $-58M | $-52M | -16.9% | -6.1% | -7.6% |
| 2022 | $9M | $-66M | $-63M | $-49M | -19.7% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 8.61 | 8.08 | 10.59 | 10 |
| Operating Revenue | - | 8.61 | 8.08 | 10.59 | 10 |
| Operating Expense | - | 75.70 | 81.06 | 109.44 | 167.67 |
| Research And Development | - | 53.44 | 54.92 | 68.39 | 125.90 |
| Selling General And Administration | - | 22.26 | 26.14 | 41.05 | 41.77 |
| Total Expenses | - | 75.70 | 81.06 | 109.44 | 167.67 |
| Operating Income | - | -67.09 | -72.98 | -98.85 | -157.67 |
| Total Operating Income As Reported | - | -67.09 | -72.98 | -98.85 | -157.67 |
| EBITDA | - | -66.25 | -71.02 | -96.79 | -155.64 |
| Normalized EBITDA | - | -66.25 | -71.02 | -96.79 | -155.64 |
| EBIT | - | -67.09 | -72.98 | -98.85 | -157.67 |
| Interest Income | - | 4.03 | 14.69 | 29.85 | 44.04 |
| Interest Expense | 0 | - | - | - | - |
| Net Interest Income | - | 4.03 | 14.69 | 29.85 | 44.04 |
| Interest Income Non Operating | - | 4.03 | 14.69 | 29.85 | 44.04 |
| Interest Expense Non Operating | 0 | - | - | - | - |
| Net Non Operating Interest Income Expense | - | 4.03 | 14.69 | 29.85 | 44.04 |
| Pretax Income | - | -63.06 | -58.29 | -68.99 | -113.62 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -63.06 | -58.29 | -68.99 | -113.62 |
| Net Income From Continuing And Discontinued Operation | - | -63.06 | -58.29 | -68.99 | -113.62 |
| Net Income From Continuing Operation Net Minority Interest | - | -63.06 | -58.29 | -68.99 | -113.62 |
| Net Income | - | -63.06 | -58.29 | -68.99 | -113.62 |
| Net Income Common Stockholders | - | -63.06 | -58.29 | -68.99 | -113.62 |
| Net Income Including Noncontrolling Interests | - | -63.06 | -58.29 | -68.99 | -113.62 |
| Normalized Income | - | -63.06 | -58.29 | -68.99 | -113.62 |
| Diluted NI Availto Com Stockholders | - | -63.06 | -58.29 | -68.99 | -113.62 |
| Basic Average Shares | 23.53 | 41.47 | 44.02 | 53.75 | - |
| Diluted Average Shares | 23.53 | 41.47 | 44.02 | 53.75 | - |
| Reconciled Depreciation | - | 0.84 | 1.96 | 2.06 | 2.03 |
| General And Administrative Expense | - | 22.26 | 26.14 | 41.05 | 41.77 |
| Other Gand A | - | 22.26 | 26.14 | 41.05 | 41.77 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Janux Therapeutics, Inc.this co. | JANX | $839M | -7.39 | 0.88 | -11.9% | -5.20 |
| Talkspace, Inc. | TALK | $871M | 111.78 | 7.44 | 6.7% | 129.10 |
| Arbutus Biopharma Corporation | ABUS | $859M | -25.65 | 11.22 | -43.7% | -25.48 |
| Theravance Biopharma, Inc. | TBPH | $844M | 7.97 | 2.84 | 35.7% | 5.34 |
| ORIC Pharmaceuticals, Inc. | ORIC | $830M |
| - |
| - |
| - |
| - |
| - |
| - |
| -6.41 |
| 2.16 |
| -33.7% |
| -5.56 |
| LB Pharmaceuticals Inc | LBRX | $829M | -32.88 | 2.75 | -8.4% | -19.35 |
| Amphastar Pharmaceuticals, Inc. | AMPH | $825M | 8.41 | 1.05 | 12.4% | 6.17 |
| Sana Biotechnology, Inc. | SANA | $824M | -3.37 | 5.12 | -151.8% | -4.31 |
| Replimune Group, Inc. | REPL | $815M | -3.30 | 1.96 | -59.5% | -3.31 |
| Peer Median | - | -3.33 | 2.80 | -21.0% | -3.81 | |